The With Or Without Olecranon K-wires Trial (WOW-OK)

January 19, 2023 updated by: Region Skane

The With Or Without Olecranon K-wire (WOW OK) Trial of Tension Band Wire Fixation Versus Cerclage Fixation Without K-wires in Displaced Stable Olecranon Fractures

Fractures of the elbow tip (olecranon) that leave the elbow joint stable but where the fracture ends are separated (Mayo type 2a and 2b) can be treated with pins and a metal wire (tension band wiring, TBW) or metal wiring alone (cerclage fixation, CF ). Previous studies have reported high re-operation and complication rates following TBW. The current study's hypothesis, based on two retrospective studies, is that CF of these fractures yield lower re-operation rates compared with TBW. The investigators also hypothesize that the overall complication rate will be lower following CF. The aim is to investigate this hypothesis in a randomized controlled trial. Patients that are 18 years or older with Mayo type 2a and 2b olecranon fractures at Skåne University hospital will be invited to the study. Participation is voluntary. Patients who accept participation will be randomly assigned to surgery by either TBW or cerclage fixation. Two hundred participants will be followed by physiotherapists for 36 months post-surgery assessing re-operations, complications, patient reported outcome, and elbow function.

Study Overview

Status

Recruiting

Conditions

Detailed Description

The complete study protocol including a detailed description of the trial will be published in a journal before the start of the trial.

Olecranon fractures account for approximately 20% of all proximal fractures of the forearm. Stable, undisplaced fractures (Mayo type 1a and 1b) are routinely treated non-operatively, while displaced and unstable fractures (Mayo type 3a and 3b) are typically operated with plate fixation. Stable, displaced fractures (Mayo type 2a and 2b) are often treated with tension band wiring (TBW) or plate fixation. TBW is associated with soft tissue irritation and high re-operation rates with hardware removal, ranging from 25% to 84% in the literature. Plate fixation was associated with fewer re-operations compared with TBW in a randomized controlled trial, but complications following plate fixation were more severe. A Cochrane review from 2014 did not find any significant support favouring either of the two methods. Non-operative treatment of Mayo type 2a and 2b fractures can yield acceptable results in elderly patients, but is not routinely used in younger individuals with higher functional demands. Two previous retrospective studies from 2002 and 2021 reported that Mayo 2a and 2b fractures can be operated with cerclage fixation alone yielding half the re-operation rates when compared to TBW. As of April 2022 there are two studies (one active (NCT03280602) and one completed (NCT01391936)) comparing TBW vs plate fixation, three studies (two active (NCT04670900 and NCT04401462) and one terminated (NCT01397643)) comparing non-operative vs operative treatment in elderly and one active study (NCT04189185) comparing TBW vs suture fixation registered on this site. The hypothesis of the current study is that the re-operation rate and the complication rate will be lower following CF compared with TBW while yielding equal results in other outcome measures. The aim is to to investigate this in a prospective randomized clinical trial.

Methodology:

All patients presenting at Skåne University Hospital in Malmö and Lund, Sweden, with olecranon fractures of Mayo type 2a and 2b will be invited to participate in the study if they do not meet any exclusion criteria. Potential subjects will be asked to sign a consent form after receiving written and oral information about the trial. Subjects will be randomized 1:1 to surgery with TBW or cerclage. 200 subjects will be recruited based on sample size calculations derived from the re-operation frequency in a previous study (PMID: 34236459)

Baseline descriptive data will be collected at inclusion or in the peri-operative period. Operation time, intra-operative effective radiation dose and radiation time will be recorded. Subjects will be invited to follow-up to a physiotherapist at 2 weeks, 6 weeks, 3 months, 12 months and 36 months after the operation assessing re-operations, complications, post-operative antibiotics, range of elbow motion, grip strength, the Quick Disabilities of the Arm, Shoulder and Hand score (Quick-DASH, references PMID: 8773720 and 6709254), overall patient satisfaction, pain, return to work and secondary dislocation. The Short Musculoskeletal Function Assessment (SMFA, references PMID: 27994082 and 14763711) score will be assessed 12 months post-operatively. The physiotherapist will be masked to the treatment method. At 6 months one radiograph will be collected for assessment of non-union.

The primary outcome measure will be re-operations. Secondary outcome measures will be patient reported outcome measures and complications. Tertiary outcome measures are post-operative range of motion and grip strength, secondary dislocation rate, time to return to work after surgery, operation time, effective intra-operative radiation dose and radiation time. The hypothesis of the current study is that cerclage fixation will yield less re-operations, less overall complications and less severe complications while other outcome measures will be equal.

Study Type

Interventional

Enrollment (Anticipated)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Sustained Olecranon type fracture of Mayo 2a or 2b
  • Seeking healthcare in at the Skåne University Hospital in Lund and Malmö, Sweden.

Exclusion Criteria:

  • Subjects unable to participate in follow up (for example subjects with active substance abuse, dementia, inability to communicate or understand the questionnaires or subjects living in other administrative healthcare regions).
  • Subjects unable to give informed written consent.
  • Subject where non operative treatment is indicated due to frailty or severe ongoing disease.
  • Fracture not operated within 14 days from the date the fracture was sustained.
  • Subjects with severe open fractures of Gustilo-Anderson class III
  • Subject with pathological fractures from metastatic disease.
  • Subject with simultaneous or previous severe injury to the same arm are excluded for patient reported outcome measures but included for all other outcomes.
  • Subjects with previously severe injuries to the same arm will be excludes for PROM analyses but included for reoperation and complication analyses.
  • Subjects operated by an orthopedic trauma surgeons that did not attended our education on the study and the interventions, unless surgery is supervised by an orthopedic surgeon that has attended the education the subject will not be excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Cerclage
Intervention by cerclage fixation.
The intervention is by surgical open reduction and internal fixation of the fracture using two 1.0mm cerclage.
Active Comparator: Tension Band Wiring
Intervention by tension band wiring
The intervention is by surgical open reduction and internal fixation of the fracture using a 1.0mm cerclage and two 1.6 mm k-wires as described in AO-guidelines.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Re-operation rate 1.5 months.
Time Frame: Recorded at 1.5 months after intervention.
Total re-operation rate of the operated elbow regardless of cause.
Recorded at 1.5 months after intervention.
Re-operation rate 3 months.
Time Frame: Recorded at 3 months after intervention.
Total re-operation rate of the operated elbow regardless of cause.
Recorded at 3 months after intervention.
Re-operation rate 12 months.
Time Frame: Recorded at 12 months after intervention.
Total re-operation rate of the operated elbow regardless of cause.
Recorded at 12 months after intervention.
Re-operation rate 36 months.
Time Frame: Recorded at 36 months after intervention.
Total re-operation rate of the operated elbow regardless of cause.
Recorded at 36 months after intervention.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Complication rate 1.5 months.
Time Frame: Recorded at 1.5 months after intervention.
Total complication rate.
Recorded at 1.5 months after intervention.
Complication rate 3 months.
Time Frame: Recorded at 3 months after intervention.
Total complication rate.
Recorded at 3 months after intervention.
Complication rate 12 months.
Time Frame: Recorded at 12 months after intervention.
Total complication rate.
Recorded at 12 months after intervention.
Complication rate 36 months.
Time Frame: Recorded at 36 months after intervention.
Total complication rate.
Recorded at 36 months after intervention.
Complication severity 1.5 months.
Time Frame: Recorded at 1.5 months after intervention.
Complication severity classified with the Clavien-Dindo Classification.
Recorded at 1.5 months after intervention.
Complication severity 3 months.
Time Frame: Recorded at 3 months after intervention.
Complication severity classified with the Clavien-Dindo Classification.
Recorded at 3 months after intervention.
Complication severity 12 months.
Time Frame: Recorded at 12 months after intervention.
Complication severity classified with the Clavien-Dindo Classification.
Recorded at 12 months after intervention.
Complication severity 36 months.
Time Frame: Recorded at 36 months after intervention.
Complication severity classified with the Clavien-Dindo Classification.
Recorded at 36 months after intervention.
Quick-DASH 1.5 months.
Time Frame: 1.5 months after intervention.
Quick-DASH questionnaire assessed by subjects. See references PMID: 8773720 and 6709254.
1.5 months after intervention.
Quick-DASH 3 months.
Time Frame: 3 months after intervention.
Quick-DASH questionnaire assessed by subjects. See references PMID: 8773720 and 6709254.
3 months after intervention.
Quick-DASH 12 months.
Time Frame: 12 months after intervention.
Quick-DASH questionnaire assessed by subjects. See references PMID: 8773720 and 6709254.
12 months after intervention.
Quick-DASH 36 months.
Time Frame: 36 months after intervention.
Quick-DASH questionnaire assessed by subjects. See references PMID: 8773720 and 6709254.
36 months after intervention.
SMFA 12 months
Time Frame: 12 months after intervention.
SMFA-questionnaire assessed by subjects. See reference PMID: 27994082 and 14763711
12 months after intervention.
Pain level 1.5 months.
Time Frame: Recorded at 1.5 months after intervention
Subjective pain level in motion and at rest. Measured with a visual analog scale.
Recorded at 1.5 months after intervention
Pain level 3 months.
Time Frame: Recorded at 3 months after intervention.
Subjective pain level in motion and at rest. Measured with a visual analog scale.
Recorded at 3 months after intervention.
Pain level 12 months,
Time Frame: Recorded at 12 months after intervention.
Subjective pain level in motion and at rest. Measured with a visual analog scale.
Recorded at 12 months after intervention.
Pain level 36 months.
Time Frame: Recorded at 36 months after intervention.
Subjective pain level in motion and at rest. Measured with a visual analog scale.
Recorded at 36 months after intervention.
Overall satisfaction 1.5 months.
Time Frame: Recorded at 1.5 months after intervention.
Subjective overall satisfaction level. Measured with a visual analog scale.
Recorded at 1.5 months after intervention.
Overall satisfaction 3 months.
Time Frame: Recorded at 3 months after intervention.
Subjective overall satisfaction level. Measured with a visual analog scale.
Recorded at 3 months after intervention.
Overall satisfaction 12 months.
Time Frame: Recorded at 12 months after intervention.
Subjective overall satisfaction level. Measured with a visual analog scale.
Recorded at 12 months after intervention.
Overall satisfaction 36 months.
Time Frame: Recorded at 36 months after intervention.
Subjective overall satisfaction level. Measured with a visual analog scale.
Recorded at 36 months after intervention.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Grip strength 0.5 months.
Time Frame: Recorded at 0.5 months after intervention.
Grips strength will be evaluated using a JAMAR dynamometer as detailed in the Swedish National Quality Register for Hand Surgery (HAKIR)
Recorded at 0.5 months after intervention.
Grip strength 1.5 months.
Time Frame: Recorded at 1.5 months after intervention.
Grips strength will be evaluated using a JAMAR dynamometer as detailed in the Swedish National Quality Register for Hand Surgery (HAKIR)
Recorded at 1.5 months after intervention.
Grip strength 3 months.
Time Frame: Recorded at 3 months after intervention.
Grips strength will be evaluated using a JAMAR dynamometer as detailed in the Swedish National Quality Register for Hand Surgery (HAKIR)
Recorded at 3 months after intervention.
Grip strength 12 months.
Time Frame: Recorded at 12 months after intervention.
Grips strength will be evaluated using a JAMAR dynamometer as detailed in the Swedish National Quality Register for Hand Surgery (HAKIR)
Recorded at 12 months after intervention.
Grip strength 36 months.
Time Frame: Recorded at 36 months after intervention.
Grips strength will be evaluated using a JAMAR dynamometer as detailed in the Swedish National Quality Register for Hand Surgery (HAKIR)
Recorded at 36 months after intervention.
Range of motion 0.5 months.
Time Frame: Recorded at 0.5 months after intervention.
Active extension, flexion, pronation and supination will be evaluated using a goniometer following the Swedish National Quality Register for Hand Surgery (HAKIR) guidelines.
Recorded at 0.5 months after intervention.
Range of motion 1.5 months.
Time Frame: Recorded at 1.5 months after intervention.
Active extension, flexion, pronation and supination will be evaluated using a goniometer following the Swedish National Quality Register for Hand Surgery (HAKIR) guidelines.
Recorded at 1.5 months after intervention.
Range of motion 3 months.
Time Frame: Recorded at 3 months after intervention.
Active extension, flexion, pronation and supination will be evaluated using a goniometer following the Swedish National Quality Register for Hand Surgery (HAKIR) guidelines.
Recorded at 3 months after intervention.
Range of motion 12 months.
Time Frame: Recorded at 12 months after intervention.
Active extension, flexion, pronation and supination will be evaluated using a goniometer following the Swedish National Quality Register for Hand Surgery (HAKIR) guidelines.
Recorded at 12 months after intervention.
Range of motion 36 months.
Time Frame: Recorded at 36 months after intervention.
Active extension, flexion, pronation and supination will be evaluated using a goniometer following the Swedish National Quality Register for Hand Surgery (HAKIR) guidelines.
Recorded at 36 months after intervention.
Time to return to work 1.5 months.
Time Frame: Recorded at 1.5 months after intervention.
Time to return to work in days will be evaluated for all working subjects.
Recorded at 1.5 months after intervention.
Time to return to work 3 months.
Time Frame: Recorded at 3 months after intervention.
Time to return to work in days will be evaluated for all working subjects.
Recorded at 3 months after intervention.
Time to return to work 12 months.
Time Frame: Recorded at 12 months after intervention.
Time to return to work in days will be evaluated for all working subjects.
Recorded at 12 months after intervention.
Time to return to work 36 months.
Time Frame: Recorded at 36 months after intervention.
Time to return to work in days will be evaluated for all working subjects.
Recorded at 36 months after intervention.
Secondary dislocation rate.
Time Frame: 6 months after intervention.
Secondary dislocation rate will be assessed with a one lateral view radiograph of the operated elbow.
6 months after intervention.
Intra-operative fluoroscopy radiation level.
Time Frame: Peri-operative.
Intra-operative fluoroscopy radiation DAP will be recorded at the time of surgery from the fluoroscopy machine used.
Peri-operative.
Intra-operative fluoroscopy time.
Time Frame: Peri-operative.
Intra-operative fluoroscopy time will be recorded at the time of surgery from the fluoroscopy machine used.
Peri-operative.
Antibiotic treatment 1.5.
Time Frame: Recorded at 1.5 months after intervention.
Any unplanned prescription of antibiotics after the intervention related to the injury.
Recorded at 1.5 months after intervention.
Antibiotic treatment 3.
Time Frame: Recorded at 3 months after intervention.
Any unplanned prescription of antibiotics after the intervention related to the injury.
Recorded at 3 months after intervention.
Antibiotic treatment 12.
Time Frame: Recorded at 12 months after intervention.
Any unplanned prescription of antibiotics after the intervention related to the injury.
Recorded at 12 months after intervention.
Antibiotic treatment 36.
Time Frame: Recorded at 36 months after intervention.
Any unplanned prescription of antibiotics after the intervention related to the injury.
Recorded at 36 months after intervention.
Surgical time.
Time Frame: Peri-operative.
Time from incision to completed wound closure will be recorded during surgery.
Peri-operative.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Daniel Wenger, MD, PhD, Department of Orthopedics, Skåne University Hospital and Lund University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2023

Primary Completion (Anticipated)

September 1, 2029

Study Completion (Anticipated)

September 1, 2029

Study Registration Dates

First Submitted

November 16, 2022

First Submitted That Met QC Criteria

December 11, 2022

First Posted (Actual)

December 20, 2022

Study Record Updates

Last Update Posted (Actual)

January 20, 2023

Last Update Submitted That Met QC Criteria

January 19, 2023

Last Verified

November 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Olecranon Fracture

Clinical Trials on Cerclage fixation

3
Subscribe